Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Mind Medicine (MindMed) Inc. - Common Shares (NQ: MNMD )

8.180 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mind Medicine (MindMed) Inc. - Common Shares

< Previous 1 2
...
26 27 28 29 30 31 32 33 Next >
Rising Prevalence of Mental Depression & Anxiety Major Drivers Propelling Demand In Psychedelic Drugs Market
Via FinancialNewsMedia
Psyched: GH Research Debuts on Nasdaq, Compass Reaches Psilocybin Research Milestone, Maxim Gives BUY Rating to 10 Psychedelics Companies
Irish 5-MeO-DMT Company GH Research Debuts On Nasdaq GH Research, a Dublin-based company studying the potential o... 
Via Benzinga
The MindMed Psychedelic Revolution Will Take Years to Come to Fruition
MNMD stock aspires to be a lot to many but could flop. Prices are low, risk is high and speculators could become savants. 
Via InvestorPlace
J.R. Rahn Steps Down As MindMed CEO
Mind Medicine Inc. (NASDAQ:MNMD), more commonly known as M... 
Via Benzinga
Maxim Group Gives Buy Rating To 10 Psychedelic Stocks: Compass, MindMed, Cybin, Field Trip And More
Institutional analysts are taking a liking to the industry ... 
Via Benzinga
Video: Talking Cannabis With Aurora Co-Founder Terry Booth | Benzinga Cannabis Insider 6/29
Benzinga’s 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Get a Dose of Innovative Science With Mind Medicine
MNMD stock ran high last year, but the story is still being written as Mind Medicine marks progress with its psychedelics-based treatments. 
Via InvestorPlace
Psychedelics-Focused MindMed Joins FTSE Russell 3000 Index, 'A True Honor'
A psychedelics-focused medicine company MindMed (NASDAQ: 
Via Benzinga
Pandemic Fallout: 6 Mental Health Stocks To Watch
One of the most devastating long-term impacts of the COVID-19 pandemic may be the toll it has taken on people’s mental health. The next globa... 
Via Benzinga
Exposures COVID-19
MindMed Can Play a Big Role in the Growing Mental Wellness Industry
With Covid-19 increasing the frequency of mental health problems, MNMD stock is a way to invest in psychedelics, which are seeing legitimacy. 
Via InvestorPlace
Exposures COVID-19
Why This MindMed Analyst Is Bullish: 'One Of The Most Diverse Pipelines In Psychedelics'
Mind Medicine (MindMed) Inc (NASDAQ:MNMD) shares traded hi... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2021
Upgrades For Toll Brothers Inc (NYSE: 
Via Benzinga
Cannabis Movers & Shakers: HempFusion, Decibel, ARCA, Love Hemp, MindMed, Halo
HempFusion Wellness Promotes VP And Controller Maria Leal To Interim CFO HempFusion Wellness Inc. (TSX: 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Atai IPO Day An Underwhelming Event
The IPO of atai Life Sciences was arguably the most-anticipated event in the emerging psychedelic drug industry. It failed to live up to expectations. 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Psyched: Atai Life Sciences Hits Nasdaq, Canada To Fund Ketamine Trials, Mydecine Launches AI Drug-Discovery Platform
Atai Life Sciences (NASDAQ: ATAI) made its highly-anticipated Nasdaq... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Peter Thiel-backed Psychedelics Company Rings Nasdaq Bell: Atai Life Sciences Goes Public
Atai Life Sciences (NASDAQ:ATAI), a biotech company in the... 
Via Benzinga
New Psychedelic Drug Stock To Debut After Upsized IPO Prices At High End
Atai Life Sciences, a backer of psychedelic-drug developers, will start trading Friday, after an upsized offering for the Atai IPO. 
Via Investor's Business Daily
Topics Initial Public Offering
Exposures Securities Market
Is Mind Medicine a Buy?
It offers a great way to tap into the psychedelics market -- but is it too risky of an investment right now? 
Via The Motley Fool
Topics Cannabis
Exposures Cannabis
Could Mind Medicine Be a Millionaire-Maker Stock?
Yes, but with the chance of great reward comes substantial risk. 
Via The Motley Fool
Recent Surge for Intellectual Property & Patents in Psychedelic Therapies & Drug Development
Via FinancialNewsMedia
Topics Intellectual Property
Exposures Intellectual Property
Psyched: Atai's $214M IPO, MindMed CEO Resigns, Field Trip Applies To Nasdaq, Cybin And Novamind Target Frontline Health Workers
Atai Launches $214 Million Nasdaq IPO Offering Psychedelics biotech platform Atai life Sciences has announced an initi... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Mind Medicine Stock Might Still Be Worth the Risk Here
The rampant addiction crisis in America requires a new effective solution, which may suit MNMD stock well. 
Via InvestorPlace
EXCLUSIVE: Psychedelics Pioneer J.R. Rahn Unpacks Decision To Leave MindMed As CEO
Mind Medicine (MindMed) Inc (NASDAQ: MNMD) (NEO: MMED), a biotech company focused on the field of psychedelics, formally announced this week that J.R. Rahn, the company’s co... 
Via Benzinga
Here's How This Psychedelic Drug CEO Sees The Industry Evolving
Competition within legal psychedelic drugs has only barely taken shape. Companies focused on therapy will be the ultimate winners, one CEO said. 
Via Investor's Business Daily
Why Shares of MindMed Dropped 13% in May
Froth from its uplisting is having an impact. 
Via The Motley Fool
What Do You Really Know About Psychedelics And Psychedelics Stocks?
According to a new poll conducted by Hill-HarrisX, 65% of registered voters say psychedelic substances do not have medical use. That... 
Via Benzinga
Why the North America Psychedelic Drugs Market is Expected to Grow With the Fastest CAGR for Next Several Years
Via FinancialNewsMedia
Topics Law Enforcement
Exposures Legal
Psyched: First Psychedelics ETF Comes To The US, Bills Move Forward In Texas, California and New York
Psychedelics ETFs Are Gaining Traction Defiance ETFs launched the “Next Gen Altered Experience ETF,” the ... 
Via Benzinga
The Mind Medicine Stock Story Has an Awful Lot of Holes in It
MNMD stock has immense potential, but the plethora of risks surrounding it limit its attractiveness at this time. 
Via InvestorPlace
Psychedelic Drug Stocks: A Big Healthcare Footprint At A Small Price
Fuelled by hundreds of millions in startup capital, psychedelic drug companies are powering a Revolution in healthcare. But with the sector currently in a trough, investors can still enter at... 
Via Talk Markets
< Previous 1 2
...
26 27 28 29 30 31 32 33 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.